Skip to main content
Clinical Trials/NL-OMON25726
NL-OMON25726
Recruiting
Not Applicable

European Active Surveillance of Renal Cell Carcinoma Study

niversity of Eastern Piedmont Department of Translational Medicine0 sites400 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Renal Cell Carcinoma
Sponsor
niversity of Eastern Piedmont Department of Translational Medicine
Enrollment
400
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
niversity of Eastern Piedmont Department of Translational Medicine

Eligibility Criteria

Inclusion Criteria

  • oMales or females, age \= 18 years.
  • oIncidental diagnosis at imaging (ultrasonography, CT, MRI) of a solid renal mass \< 4 cm in maximum diameter (pT1a).
  • oHistologically confirmed RCC by percutaneous needle biopsy at diagnosis. All RCC subtypes are eligible for the study.
  • oPatients unfit for active treatment due to advanced age, or co\-morbidity, or choosing to avoid active treatment.
  • oSigned Informed consent.
  • oPreparedness to comply with percutaneous tumor biopsy and a close follow\-up protocol

Exclusion Criteria

  • oRenal tumors with a non\-RCC histology (sarcomas, lymphomas, etc.).
  • oPresence of metastatic disease at diagnosis
  • oTumor related symptoms at presentation.
  • oPatients with known genetic diseases associated with RCC (VHL, BHD, HLRCC, etc.).
  • oPatients unsuitable for biopsy due to need for concomitant anticoagulation or anti\-platelet drug use which cannot be transiently discontinued.
  • oPatients unsuitable for biopsy due to tumor location or small tumor size.
  • oPatients with concurrent systemic treatment for another cancer.
  • oPatients with estimated life expectancy \< 1 year.

Outcomes

Primary Outcomes

Not specified

Similar Trials